Abstract
Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from activated and/or apoptotic cells. Although described since 1967 by Wolf [1], it is only since the 1990’s that microparticles have been considered as biomarkers as well as potential mediators of biological messages between cells [2] by acting as paracrine and endocrine vectors. Detection of microparticles has been performed in biological fluids (blood, synovial fluid, saliva for instance) and some solid tissues but also from the culture medium [3]. Levels of circulating microparticles are enhanced in a large number of pathological states including cardiovascular and metabolic disorders associated with insulin resistance and this has been linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This review highlights the increasing impact of microparticles in major cardiovascular pathological situations associated with metabolic derangements.
Keywords: Diabetes, endothelium, extracellular vesicles, hypertension, obesity.
Current Vascular Pharmacology
Title:Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components
Volume: 12 Issue: 3
Author(s): Abdelali Agouni, Ramaroson Andriantsitohaina and Maria C. Martinez
Affiliation:
Keywords: Diabetes, endothelium, extracellular vesicles, hypertension, obesity.
Abstract: Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from activated and/or apoptotic cells. Although described since 1967 by Wolf [1], it is only since the 1990’s that microparticles have been considered as biomarkers as well as potential mediators of biological messages between cells [2] by acting as paracrine and endocrine vectors. Detection of microparticles has been performed in biological fluids (blood, synovial fluid, saliva for instance) and some solid tissues but also from the culture medium [3]. Levels of circulating microparticles are enhanced in a large number of pathological states including cardiovascular and metabolic disorders associated with insulin resistance and this has been linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This review highlights the increasing impact of microparticles in major cardiovascular pathological situations associated with metabolic derangements.
Export Options
About this article
Cite this article as:
Agouni Abdelali, Andriantsitohaina Ramaroson and Martinez C. Maria, Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/1570161112666140423223148
DOI https://dx.doi.org/10.2174/1570161112666140423223148 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry MicroRNAs and the Heart: Small Things Do Matter
Current Topics in Medicinal Chemistry Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Pure Polyphenols Applications for Cardiac Health and Disease
Current Pharmaceutical Design